Concepts (254)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Robotic Surgical Procedures | 13 | 2025 | 170 | 6.340 |
Why?
|
| Lung Neoplasms | 20 | 2026 | 702 | 5.640 |
Why?
|
| Thoracic Surgery | 9 | 2026 | 79 | 3.660 |
Why?
|
| Thoracic Surgical Procedures | 7 | 2025 | 42 | 3.510 |
Why?
|
| Thoracic Surgery, Video-Assisted | 7 | 2025 | 62 | 2.690 |
Why?
|
| Esophageal Neoplasms | 5 | 2024 | 94 | 2.470 |
Why?
|
| Pneumonectomy | 8 | 2026 | 130 | 2.470 |
Why?
|
| Surgeons | 5 | 2025 | 185 | 2.190 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 6 | 2025 | 184 | 1.920 |
Why?
|
| Early Detection of Cancer | 3 | 2026 | 325 | 1.900 |
Why?
|
| Thoracic Wall | 3 | 2025 | 21 | 1.840 |
Why?
|
| Pleural Neoplasms | 5 | 2025 | 19 | 1.830 |
Why?
|
| Esophagectomy | 4 | 2024 | 53 | 1.360 |
Why?
|
| Databases, Factual | 9 | 2025 | 879 | 1.250 |
Why?
|
| Thoracotomy | 4 | 2025 | 48 | 1.230 |
Why?
|
| Mediastinal Neoplasms | 2 | 2025 | 21 | 1.190 |
Why?
|
| Multiple Pulmonary Nodules | 2 | 2026 | 22 | 1.170 |
Why?
|
| Societies, Medical | 7 | 2026 | 400 | 0.950 |
Why?
|
| Conversion to Open Surgery | 2 | 2025 | 13 | 0.930 |
Why?
|
| Thoracic Neoplasms | 1 | 2025 | 14 | 0.920 |
Why?
|
| Mesothelioma | 4 | 2014 | 28 | 0.910 |
Why?
|
| Thoracoscopy | 1 | 2025 | 28 | 0.900 |
Why?
|
| Humans | 55 | 2026 | 64729 | 0.890 |
Why?
|
| Anastomotic Leak | 2 | 2023 | 36 | 0.870 |
Why?
|
| Suture Techniques | 1 | 2024 | 94 | 0.840 |
Why?
|
| Precision Medicine | 1 | 2025 | 126 | 0.830 |
Why?
|
| Healthcare Disparities | 2 | 2025 | 404 | 0.770 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2023 | 39 | 0.760 |
Why?
|
| Esophageal Achalasia | 1 | 2023 | 35 | 0.760 |
Why?
|
| Tracheoesophageal Fistula | 1 | 2022 | 5 | 0.740 |
Why?
|
| Herpes Simplex | 1 | 2022 | 49 | 0.710 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2026 | 1656 | 0.700 |
Why?
|
| GPI-Linked Proteins | 5 | 2014 | 39 | 0.690 |
Why?
|
| Molecular Imaging | 2 | 2011 | 52 | 0.660 |
Why?
|
| Clinical Competence | 2 | 2024 | 723 | 0.650 |
Why?
|
| Retrospective Studies | 16 | 2025 | 6803 | 0.650 |
Why?
|
| Unnecessary Procedures | 1 | 2020 | 49 | 0.640 |
Why?
|
| Radiation Dosage | 1 | 2020 | 140 | 0.610 |
Why?
|
| Biomedical Research | 1 | 2021 | 270 | 0.560 |
Why?
|
| Postoperative Complications | 4 | 2025 | 1309 | 0.510 |
Why?
|
| Metastasectomy | 1 | 2016 | 3 | 0.480 |
Why?
|
| Treatment Outcome | 9 | 2024 | 5758 | 0.460 |
Why?
|
| Stomach | 2 | 2012 | 87 | 0.440 |
Why?
|
| Dyspnea | 2 | 2012 | 120 | 0.430 |
Why?
|
| Biomarkers, Tumor | 3 | 2013 | 522 | 0.420 |
Why?
|
| Disease Models, Animal | 2 | 2012 | 2270 | 0.420 |
Why?
|
| Disease Management | 1 | 2016 | 233 | 0.410 |
Why?
|
| Anastomosis, Surgical | 2 | 2024 | 119 | 0.410 |
Why?
|
| Neoplasm Staging | 7 | 2024 | 539 | 0.400 |
Why?
|
| Internship and Residency | 3 | 2025 | 810 | 0.390 |
Why?
|
| Tumor Burden | 2 | 2021 | 75 | 0.390 |
Why?
|
| Lymph Nodes | 2 | 2011 | 231 | 0.390 |
Why?
|
| Diaphragmatic Eventration | 1 | 2012 | 2 | 0.370 |
Why?
|
| Hernia, Diaphragmatic | 1 | 2012 | 3 | 0.370 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2024 | 126 | 0.370 |
Why?
|
| Pneumopericardium | 1 | 2012 | 3 | 0.370 |
Why?
|
| Gastric Fistula | 1 | 2012 | 4 | 0.370 |
Why?
|
| Puerperal Disorders | 1 | 2012 | 15 | 0.370 |
Why?
|
| Epithelioid Cells | 1 | 2012 | 4 | 0.370 |
Why?
|
| Pericardium | 1 | 2012 | 35 | 0.360 |
Why?
|
| Education, Medical, Graduate | 2 | 2025 | 350 | 0.360 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2014 | 201 | 0.360 |
Why?
|
| Lymphatic Metastasis | 2 | 2011 | 90 | 0.350 |
Why?
|
| Female | 22 | 2025 | 33739 | 0.350 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2012 | 65 | 0.350 |
Why?
|
| Lung | 4 | 2021 | 965 | 0.350 |
Why?
|
| Cesarean Section | 1 | 2012 | 100 | 0.340 |
Why?
|
| Surgical Flaps | 1 | 2012 | 116 | 0.330 |
Why?
|
| Models, Animal | 1 | 2011 | 241 | 0.330 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 220 | 0.330 |
Why?
|
| Monitoring, Intraoperative | 1 | 2010 | 47 | 0.330 |
Why?
|
| Oximetry | 1 | 2010 | 49 | 0.330 |
Why?
|
| Aged | 14 | 2025 | 14834 | 0.320 |
Why?
|
| Middle Aged | 15 | 2025 | 18106 | 0.320 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2010 | 90 | 0.310 |
Why?
|
| Pneumothorax | 2 | 2024 | 50 | 0.300 |
Why?
|
| Adenocarcinoma | 3 | 2022 | 364 | 0.300 |
Why?
|
| Esophagus | 2 | 2023 | 47 | 0.290 |
Why?
|
| Research Support as Topic | 1 | 2009 | 42 | 0.290 |
Why?
|
| United States | 8 | 2026 | 8041 | 0.290 |
Why?
|
| Health Care Reform | 1 | 2009 | 86 | 0.280 |
Why?
|
| Bronchogenic Cyst | 1 | 2008 | 2 | 0.280 |
Why?
|
| Male | 17 | 2025 | 30790 | 0.280 |
Why?
|
| Science | 1 | 2009 | 34 | 0.280 |
Why?
|
| Carcinoid Tumor | 1 | 2008 | 12 | 0.280 |
Why?
|
| Epidermal Cyst | 1 | 2008 | 11 | 0.270 |
Why?
|
| Splenic Diseases | 1 | 2008 | 15 | 0.270 |
Why?
|
| Neoplasms, Second Primary | 1 | 2008 | 50 | 0.270 |
Why?
|
| Insurance, Health | 1 | 2009 | 151 | 0.270 |
Why?
|
| Pancreatic Neoplasms | 2 | 2010 | 347 | 0.270 |
Why?
|
| Pancreatic Diseases | 1 | 2008 | 38 | 0.270 |
Why?
|
| Choristoma | 1 | 2008 | 24 | 0.270 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2008 | 204 | 0.260 |
Why?
|
| Quality Improvement | 2 | 2022 | 458 | 0.250 |
Why?
|
| Spleen | 1 | 2008 | 476 | 0.250 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2006 | 12 | 0.240 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 640 | 0.240 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2026 | 21 | 0.230 |
Why?
|
| Prognosis | 6 | 2022 | 1770 | 0.230 |
Why?
|
| Delphi Technique | 1 | 2026 | 110 | 0.230 |
Why?
|
| Computer-Assisted Instruction | 1 | 2006 | 79 | 0.230 |
Why?
|
| Animals | 10 | 2025 | 21292 | 0.220 |
Why?
|
| Emergencies | 1 | 2025 | 122 | 0.220 |
Why?
|
| Urinary Bladder | 1 | 2024 | 48 | 0.220 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2006 | 158 | 0.210 |
Why?
|
| Aorta | 1 | 2024 | 109 | 0.210 |
Why?
|
| Adult | 13 | 2025 | 17230 | 0.210 |
Why?
|
| Swine | 1 | 2024 | 394 | 0.200 |
Why?
|
| Diagnosis, Differential | 4 | 2012 | 989 | 0.200 |
Why?
|
| Esophageal Sphincter, Lower | 1 | 2023 | 22 | 0.200 |
Why?
|
| Burnout, Professional | 1 | 2025 | 141 | 0.200 |
Why?
|
| Curriculum | 2 | 2024 | 603 | 0.200 |
Why?
|
| Benchmarking | 2 | 2023 | 136 | 0.200 |
Why?
|
| General Surgery | 1 | 2006 | 212 | 0.200 |
Why?
|
| Time Factors | 3 | 2024 | 3745 | 0.190 |
Why?
|
| Neoplasm Invasiveness | 4 | 2022 | 285 | 0.190 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2023 | 73 | 0.190 |
Why?
|
| Endoscopy | 1 | 2023 | 94 | 0.190 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 1211 | 0.190 |
Why?
|
| Bronchoscopes | 1 | 2022 | 9 | 0.190 |
Why?
|
| Simplexvirus | 1 | 2022 | 26 | 0.180 |
Why?
|
| Virtual Reality | 1 | 2022 | 16 | 0.180 |
Why?
|
| Bronchoscopy | 1 | 2022 | 88 | 0.180 |
Why?
|
| Learning | 1 | 2023 | 185 | 0.170 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2021 | 5 | 0.170 |
Why?
|
| Carbon Monoxide | 1 | 2021 | 63 | 0.170 |
Why?
|
| Parents | 1 | 2025 | 401 | 0.170 |
Why?
|
| Simulation Training | 1 | 2022 | 61 | 0.170 |
Why?
|
| Robotics | 1 | 2022 | 86 | 0.170 |
Why?
|
| Data Warehousing | 1 | 2020 | 7 | 0.160 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 260 | 0.160 |
Why?
|
| Medicare | 1 | 2024 | 615 | 0.160 |
Why?
|
| Diagnostic Errors | 1 | 2020 | 104 | 0.150 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 1104 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2022 | 369 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2020 | 489 | 0.140 |
Why?
|
| Colorectal Neoplasms | 2 | 2012 | 286 | 0.130 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 1689 | 0.130 |
Why?
|
| Diagnostic Imaging | 2 | 2011 | 269 | 0.130 |
Why?
|
| Follow-Up Studies | 4 | 2024 | 2483 | 0.130 |
Why?
|
| Recurrence | 2 | 2024 | 655 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2012 | 461 | 0.130 |
Why?
|
| Immunoenzyme Techniques | 2 | 2012 | 108 | 0.110 |
Why?
|
| Gallbladder Diseases | 1 | 2015 | 27 | 0.110 |
Why?
|
| Mice | 4 | 2013 | 11085 | 0.110 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2014 | 39 | 0.110 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2015 | 50 | 0.110 |
Why?
|
| Rats | 2 | 2025 | 1996 | 0.110 |
Why?
|
| Patient Selection | 2 | 2015 | 483 | 0.110 |
Why?
|
| Drainage | 2 | 2012 | 153 | 0.110 |
Why?
|
| Cell Proliferation | 3 | 2014 | 1029 | 0.110 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2014 | 100 | 0.100 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 5562 | 0.100 |
Why?
|
| Cell Movement | 2 | 2013 | 475 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2014 | 279 | 0.100 |
Why?
|
| Rupture, Spontaneous | 1 | 2012 | 22 | 0.090 |
Why?
|
| Esophageal Atresia | 1 | 2012 | 10 | 0.090 |
Why?
|
| Sternotomy | 1 | 2012 | 12 | 0.090 |
Why?
|
| Laparotomy | 1 | 2012 | 54 | 0.090 |
Why?
|
| Methods | 1 | 2011 | 40 | 0.090 |
Why?
|
| Barrett Esophagus | 1 | 2012 | 31 | 0.090 |
Why?
|
| Osteopontin | 1 | 2011 | 21 | 0.090 |
Why?
|
| Cell Adhesion | 1 | 2012 | 216 | 0.090 |
Why?
|
| Chest Pain | 1 | 2012 | 85 | 0.090 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2011 | 12 | 0.090 |
Why?
|
| Luminescent Measurements | 1 | 2011 | 39 | 0.090 |
Why?
|
| Pleurodesis | 1 | 2011 | 9 | 0.090 |
Why?
|
| Oncolytic Viruses | 1 | 2011 | 10 | 0.090 |
Why?
|
| Chest Tubes | 1 | 2011 | 17 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 211 | 0.090 |
Why?
|
| Reoperation | 1 | 2012 | 296 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 298 | 0.080 |
Why?
|
| Sus scrofa | 1 | 2010 | 30 | 0.080 |
Why?
|
| Catheters, Indwelling | 1 | 2011 | 67 | 0.080 |
Why?
|
| Cell Hypoxia | 1 | 2010 | 42 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 543 | 0.080 |
Why?
|
| Blotting, Western | 1 | 2012 | 610 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 636 | 0.080 |
Why?
|
| Young Adult | 3 | 2024 | 4771 | 0.080 |
Why?
|
| Acute Disease | 1 | 2012 | 665 | 0.080 |
Why?
|
| Palliative Care | 2 | 2011 | 245 | 0.080 |
Why?
|
| Solitary Fibrous Tumor, Pleural | 1 | 2010 | 1 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 1 | 2012 | 870 | 0.080 |
Why?
|
| Flow Cytometry | 1 | 2012 | 666 | 0.080 |
Why?
|
| Intestines | 1 | 2010 | 178 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2012 | 304 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2010 | 623 | 0.070 |
Why?
|
| Politics | 1 | 2009 | 37 | 0.070 |
Why?
|
| India | 1 | 2009 | 164 | 0.070 |
Why?
|
| Thigh | 1 | 2008 | 27 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 792 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2025 | 2680 | 0.070 |
Why?
|
| Kidney | 1 | 2010 | 451 | 0.070 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2008 | 66 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 228 | 0.070 |
Why?
|
| Surveys and Questionnaires | 2 | 2025 | 2753 | 0.070 |
Why?
|
| Genetic Therapy | 1 | 2014 | 821 | 0.070 |
Why?
|
| Survival Rate | 2 | 2024 | 847 | 0.060 |
Why?
|
| Length of Stay | 2 | 2024 | 822 | 0.060 |
Why?
|
| Apoptosis | 1 | 2012 | 1094 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2012 | 1572 | 0.060 |
Why?
|
| Sexual Harassment | 1 | 2025 | 16 | 0.060 |
Why?
|
| Diaphragm | 1 | 2025 | 25 | 0.060 |
Why?
|
| Feedback | 1 | 2025 | 91 | 0.060 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2026 | 61 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2012 | 2086 | 0.060 |
Why?
|
| Pleura | 1 | 2024 | 12 | 0.050 |
Why?
|
| Suicidal Ideation | 1 | 2025 | 129 | 0.050 |
Why?
|
| Emergency Service, Hospital | 1 | 2012 | 1122 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2026 | 456 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2014 | 518 | 0.050 |
Why?
|
| Breast Feeding | 1 | 2025 | 161 | 0.050 |
Why?
|
| Mice, Inbred NOD | 2 | 2014 | 526 | 0.050 |
Why?
|
| Suction | 1 | 2022 | 33 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 414 | 0.040 |
Why?
|
| Prevalence | 1 | 2025 | 1432 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 94 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 315 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 1274 | 0.040 |
Why?
|
| Neoplasms | 1 | 2011 | 1357 | 0.040 |
Why?
|
| Water | 1 | 2022 | 313 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2014 | 1556 | 0.040 |
Why?
|
| Mitosis | 1 | 2021 | 220 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2022 | 479 | 0.040 |
Why?
|
| Pregnancy | 1 | 2025 | 2363 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2015 | 3299 | 0.030 |
Why?
|
| Chimerism | 1 | 2014 | 12 | 0.030 |
Why?
|
| Operative Time | 1 | 2015 | 91 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2014 | 140 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 168 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 242 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2014 | 242 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 616 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2012 | 23 | 0.020 |
Why?
|
| Mucins | 1 | 2012 | 27 | 0.020 |
Why?
|
| Camptothecin | 1 | 2012 | 29 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2014 | 752 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 91 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2012 | 142 | 0.020 |
Why?
|
| Hepatectomy | 1 | 2012 | 63 | 0.020 |
Why?
|
| Necrosis | 1 | 2012 | 146 | 0.020 |
Why?
|
| Fibrosis | 1 | 2012 | 171 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2015 | 885 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2012 | 200 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 856 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 929 | 0.020 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2010 | 62 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2014 | 1381 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1135 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 1001 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2009 | 575 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 1210 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2009 | 2603 | 0.010 |
Why?
|
| Risk Factors | 1 | 2012 | 5393 | 0.010 |
Why?
|